Articles

  • Navigating material demands of next-gen CGTs

    Cultivating resilient, stage-appropriate supply strategies is an essential yet often overlooked part of delivering safe, effective therapies to patients.
    Wednesday, April 01, 2026
  • Electroporation-based delivery for gene editing

    New findings establish the feasibility of combining nonviral ex vivo gene editing, hepatocyte transplantation, and in vivo selection, and support the clinical translation of cell-based gene-editing therapies for inherited metabolic liver diseases.
    Wednesday, March 25, 2026
  • Reaping the spoils of CGT’s golden age

    We are living in the golden age of cell and gene therapy — but the spoils will go to those who chart a deliberate course, choose the right partners, and translate breakthrough science into sustainable commercial reality.
    Tuesday, March 10, 2026
  • Preclinical roadmap to first-in-human

    A well-designed development roadmap can be a powerful strategic asset — shaping investor confidence and guiding capital deployment. Yet questions persist around the optimal timing for roadmap buildout and how it should evolve alongside preclinical development activities and fundraising efforts.
    Thursday, March 05, 2026
  • From pirates to powerhouse

    The evolution from imitation to innovation has created an ecosystem designed to reward novel science and transformative treatment approaches — and Swiss companies are now claiming their stake.
    Tuesday, February 24, 2026
  • Swimming upstream

    Rare and ultra-rare disease patients have long been forced to struggle upstream.
    Wednesday, February 18, 2026
  • 2026 cell and gene therapy predictions

    As advanced therapies transition from promising science to industrial maturity, investors will increasingly favor late-stage programs with strong data, proven scalability and credible paths to adoption.
    Monday, February 09, 2026
  • From centralized to decentralized

    A decentralized model for cell-based products offers various benefits including fresh tissues and drug products, reduced costs, and shorter treatment times.
    Wednesday, February 04, 2026
  • Narrowing the CGT access gap

    There is significant opportunity to expand the applications of cell therapy further into rare diseases as well as to tackle widespread conditions.
    Tuesday, January 27, 2026
  • What sponsors should know about FDA’s platform technology designation

    Sponsors with a licensed gene therapy can use the same vector platform to reference manufacturing, analytical and safety data for other candidates.
    Tuesday, January 20, 2026
Page